Refine
Year of publication
Has Fulltext
- yes (211)
Is part of the Bibliography
- no (211)
Keywords
- breast cancer (13)
- Mammakarzinom (12)
- Behandlung (8)
- LHC (8)
- Metastasen (8)
- CDK4/6 (6)
- PD1/PDL1 (6)
- Prävention (6)
- Studien (6)
- prevention (6)
- treatment (6)
- metastases (5)
- Breast cancer (4)
- Risiko (4)
- risk (4)
- trials (4)
- ALICE (3)
- ALICE experiment (3)
- Hadron-Hadron Scattering (3)
- metastatic (3)
- neoadjuvant therapy (3)
- pp collisions (3)
- Alpelisib (2)
- Atezolizumab (2)
- Beauty production (2)
- Clinical Trials and Observations (2)
- Diagnostik (2)
- Früherkennung (2)
- Galaktografie (2)
- Galaktomosynthese (2)
- Heavy Ions (2)
- Heavy-ion collisions (2)
- Katherine (2)
- Lokalrezidiv (2)
- MRI (2)
- MRT (2)
- Mamma (2)
- Nachsorge (2)
- PARP (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PI3K (2)
- Prognosefaktoren (2)
- Prädiktivfaktoren (2)
- Radiotherapy (2)
- Richtlinie (2)
- Single electrons (2)
- Supportivtherapie (2)
- Tomosynthese (2)
- T‑DM1 (2)
- Ultraschall (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- alpelisib (2)
- atezolizumab (2)
- breast (2)
- diagnosis (2)
- early breast cancer (2)
- follow‑up (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- galactography (2)
- galactomosynthesis (2)
- guideline (2)
- lapatinib (2)
- local recurrence (2)
- lymphocytes (2)
- neoadjuvante Therapie (2)
- predictive factors (2)
- presenilin-1 (2)
- prognostic factors (2)
- screening (2)
- studies (2)
- supportive therapy (2)
- tomosynthesis (2)
- trastuzumab (2)
- treatment/therapy (2)
- ultrasound (2)
- 3′UTR length (1)
- 900 GeV (1)
- AD patients (1)
- APA (1)
- Acetogen (1)
- Acetogenesis (1)
- Advanced breast cancer (1)
- Alzheimer's disease (1)
- Alzheimer’s disease (1)
- Anandamide (1)
- Animal models (1)
- Antihormone therapy (1)
- Artificial Intelligence (1)
- B cell malignancies (1)
- BCOR (1)
- BCORL1 (1)
- Bezeichnungen (1)
- Biodiversity Data (1)
- Biomonitoring (1)
- Bone metastases (1)
- Borderline personality disorder (1)
- Botanical Collections (1)
- Brain metastasis (1)
- Brain tumors (1)
- C3M (1)
- C4M (1)
- CCL2 (1)
- CFIm (1)
- COVID (1)
- COVID-19 (1)
- CRISPR/Cas (1)
- CRM1 (1)
- CVID (1)
- Calorimeters (1)
- Cancer (1)
- Cancer treatment (1)
- Central nervous system metastases (1)
- Charged-particle density (1)
- Charm physics (1)
- Childhood abuse (1)
- Children and adolescents (1)
- Chromatin (1)
- Clinical variation (1)
- Cold hardiness (1)
- Cold tolerance (1)
- Compact astrophysical objects (1)
- Comparison with QCD (1)
- Complex posttraumatic stress disorder (1)
- Compression stocking (1)
- Computerspielstörung (1)
- Conservation (1)
- DNA damage (1)
- Deep vein thrombosis (1)
- Deutsch (1)
- Deutschland (1)
- Dialectical behavioural therapy (1)
- Digitization (1)
- Distribution limits (1)
- E. coli (1)
- EGFR (1)
- EP300 (1)
- EWSR1 (1)
- Elderly (1)
- Emotion (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exilliteratur (1)
- Exilschriftsteller (1)
- Exilverlag (1)
- Exosomes (1)
- FIP1 (1)
- FOXO1 (1)
- Femtoscopy (1)
- First site of metastatic disease (1)
- Flightless-I (1)
- Frailty (1)
- Freiligrath, Ferdinand (1)
- Fremdsprachenunterricht (1)
- Fußball (1)
- G-quadruplexes (1)
- Galaxies and clusters (1)
- Gene fusion (1)
- Gene regulation (1)
- General practitioners (1)
- Genome editing (1)
- German PID-NET registry (1)
- Gesellschaft (1)
- Glutathione reductase (1)
- Glücksspielstörung (1)
- HBT (1)
- HDAC4 (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (1)
- HOX gene (1)
- Hadron production (1)
- Head and neck cancer (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour production (1)
- Heinzen, Karl (1)
- Herbaria (1)
- Heregulin (1)
- High-energy astrophysics (1)
- Hypertension (1)
- ICD-11 (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Inflammation (1)
- Intensity interferometry (1)
- Jets (1)
- KCGS (1)
- Landschnecken (1)
- Lesions (1)
- Leukemia (1)
- Lipid peroxidation (1)
- Literarisches Institut (Herisau) (1)
- Lymphoid Neoplasia (1)
- MACE-seq (1)
- MEIS2 (1)
- MLL1/2 (1)
- MM-121 (1)
- Machine learning (1)
- Mesenchymal stem cells (1)
- MetVF (1)
- Meta-analysis (1)
- Metastatic (1)
- Methylene-tetrahydrofolate reductase (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Molecular subtypes (1)
- Multi-strange baryons (1)
- Myeloid Neoplasia (1)
- NCoR1 (1)
- NMR spectroscopy (1)
- Nanoscale materials (1)
- Necrosis (1)
- Neoadjuvant therapy (1)
- Neural signature (1)
- Neuroepithelial tumor (1)
- Non-small cell lung cancer (1)
- Nuclear modification factor (1)
- Oldest-old (1)
- Overwintering (1)
- PBX1 (1)
- PID prevalence (1)
- PLAGL1 (1)
- PYTHIA (1)
- Pathological complete response (1)
- Patient reported outcomes (1)
- Patterns of care (1)
- Pb–Pb (1)
- Performance of High Energy Physics Detectors (1)
- Phenotypic plasticity (1)
- Politik (1)
- Post-traumatic stress disorder (1)
- Presenilin (1)
- Proton–proton (1)
- Pulmonary embolism (1)
- RBC (1)
- Radiation Oncology (1)
- Randomised controlled trial (1)
- Reactive oxygen species (1)
- Real-time polymerase chain reaction (PCR) tests (1)
- Red blood cell transfusion (1)
- Relativistic heavy ion physics (1)
- Research Infrastructure (1)
- Revolution <1848> (1)
- SARS-CoV-2 testing (1)
- SILAC-based proteomics (1)
- SRSF3 (1)
- SRSF7 (1)
- Salivary gland carcinoma (1)
- Sarcomas (1)
- Schweiz (1)
- Semantics (1)
- Seribantumab (1)
- Single muons (1)
- Social participation (1)
- Stereotactic radiosurgery (1)
- Sub-zero exposure (1)
- Sumoylation (1)
- Superoxide dismutase (1)
- Supratentorial (1)
- Surgery (1)
- T-DM1 (1)
- TALE-homdomain protein (1)
- TERRA RNA (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TKI (1)
- Taxonomy (1)
- Totholz (1)
- Toxicity (1)
- Transverse momentum (1)
- Triple negative (1)
- Tumor heterogeneity (1)
- Venous thromboembolism (1)
- Verhaltenssucht (1)
- Wide rapidity coverage (1)
- Winter survival (1)
- Wood-Ljungdahl pathway (1)
- X-ray diffraction (1)
- accident (1)
- acute coronary syndrome (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- advanced breast cancer (1)
- amino acids (1)
- amyloid precursor protein (APP) (1)
- anaemia (1)
- anti-neural autoantibodies (1)
- antibiotic therapy (1)
- antibodies (1)
- antihormone therapy (1)
- apoptosis (1)
- archeological modeling (1)
- ascites (1)
- at-risk mental state (1)
- autoimmune encephalitis (1)
- autoimmune-mediated psychosis (1)
- b-cell lymphomas (1)
- behavioral addiction (1)
- bendamustine (1)
- biophysics (1)
- calcium (1)
- cancer (1)
- cell biology (1)
- cell death (1)
- channelrhodopsin (1)
- chemogenomic set (1)
- chemotherapy (1)
- chemotherapy regimen (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- clinical high at-risk mental state (1)
- collagen degradation marker (1)
- conformational changes (1)
- controlled nuclear import (1)
- copeptin (1)
- cytochrome c. (1)
- dPAS (1)
- diffusion-weighted magnetic resonance imaging (1)
- drug discovery (1)
- druggable genome (1)
- elderly patients (1)
- electron cryo-microscopy (1)
- folding landscapes (1)
- gambling disorder (1)
- gaming disorder (1)
- head and neck cancer (1)
- healthy control (1)
- hematopoietic stem cell transplantation (1)
- human–environment interaction (1)
- iCLIP (1)
- image-based risk modelling (1)
- immune-checkpoint inhibition (1)
- induction chemotherapy (1)
- injury (1)
- kinase inhibitor (1)
- kinetically trapped state (1)
- kinetics (1)
- leukapheresis (1)
- light-gated ion channel (1)
- liver cirrhosis (1)
- lockdown (1)
- loss-of-function (1)
- lymphoma (1)
- mTOR (1)
- machine learning (1)
- metastasis (1)
- microbial rhodopsin (1)
- mortality (1)
- mouse (1)
- multidrug resistance (1)
- multiplexed immunofluorescence (1)
- myocardial infarction (1)
- neoadjuvant chemoradiotherapy (1)
- neurogenesis (1)
- neuroimaging (1)
- oocytes (1)
- open science (1)
- oral cavity cancer (1)
- oxidative stress (1)
- p63 (1)
- pPAS (1)
- paleoclimate modeling (1)
- paleoenvironment modeling (1)
- paleoenvironment reconstruction (1)
- pancreatic cancer (1)
- pediatric intensive care (1)
- personalised therapy (1)
- pertuzumab (1)
- phenotypic screening (1)
- posttranslational modification (1)
- predictive biomarker (1)
- primary immunodeficiency (PID) (1)
- protein kinase (1)
- proteins (1)
- quality control (1)
- radiation oncology (1)
- radiomic (1)
- real-time NMR spectroscopy (1)
- registry (1)
- registry for primary immunodeficiency (1)
- risk stratification (1)
- rituximab (1)
- schizophrenia (1)
- screening routine (1)
- small molecules (1)
- spectra (1)
- spring-loaded activation (1)
- stem cell niche (1)
- structural biolog (1)
- structure elucidation (1)
- subventricular zone (1)
- surgery (1)
- survival (1)
- targeted therapy (1)
- terminology (1)
- transfusion (1)
- transgenic mice (1)
- trauma (1)
- troponin (1)
- ultra-high risk for psychosis (1)
- understudied kinase (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (104)
- Frankfurt Institute for Advanced Studies (FIAS) (89)
- Informatik (88)
- Medizin (70)
- Biowissenschaften (6)
- Biochemie und Chemie (5)
- Georg-Speyer-Haus (5)
- Institut für Wirtschaft, Arbeit, und Kultur (IWAK) (5)
- Pharmazie (5)
- Geowissenschaften (4)
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Ziele: Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.
Methoden: Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-(Patients/Interventions/Control/Outcome-)Fragen, systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.
Empfehlungen: Der Teil 1 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms: Der Stellenwert des Mammografie-Screenings wird in der aktualisierten Leitlinienversion bestätigt und bildet damit die Grundlage der Früherkennung. Neben den konventionellen Methoden der Karzinomdiagnostik wird die Computertomografie (CT) zum Staging bei höherem Rückfallrisiko empfohlen. Die Nachsorgekonzepte beinhalten Untersuchungsintervalle für die körperliche Untersuchung, Ultraschall und Mammografie, während weiterführende Gerätediagnostik und Tumormarkerbestimmungen bei der metastasierten Erkrankung Anwendung finden.
Purpose: The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer.
Methods: The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure.
Recommendations: Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women with a higher risk of recurrence. The follow-up concept includes suggested intervals between physical, ultrasound and mammography examinations, additional high-tech diagnostic procedures, and the determination of tumor markers for the evaluation of metastatic disease.
The performance of the electromagnetic calorimeter of the ALICE experiment during operation in 2010-2018 at the Large Hadron Collider is presented. After a short introduction into the design, readout, and trigger capabilities of the detector, the procedures for data taking, reconstruction, and validation are explained. The methods used for the calibration and various derived corrections are presented in detail. Subsequently, the capabilities of the calorimeter to reconstruct and measure photons, light mesons, electrons and jets are discussed. The performance of the calorimeter is illustrated mainly with data obtained with test beams at the Proton Synchrotron and Super Proton Synchrotron or in proton-proton collisions at s√=13 TeV, and compared to simulations.
The performance of the electromagnetic calorimeter of the ALICE experiment during operation in 2010–2018 at the Large Hadron Collider is presented. After a short introduction into the design, readout, and trigger capabilities of the detector, the procedures for data taking, reconstruction, and validation are explained. The methods used for the calibration and various derived corrections are presented in detail. Subsequently, the capabilities of the calorimeter to reconstruct and measure photons, light mesons, electrons and jets are discussed. The performance of the calorimeter is illustrated mainly with data obtained with test beams at the Proton Synchrotron and Super Proton Synchrotron or in proton-proton collisions at √s = 13 TeV, and compared to simulations.
The transverse momentum (pT) spectrum and nuclear modification factor (RAA) of reconstructed jets in 0–10% and 10–30% central Pb–Pb collisions at √sNN = 2.76 TeV were measured. Jets were reconstructed using the anti-kT jet algorithm with a resolution parameter of R = 0.2 from charged and neutral particles, utilizing the ALICE tracking detectors and Electromagnetic Calorimeter (EMCal). The jet pT spectra are reported in the pseudorapidity interval of |ηjet| < 0.5 for 40 < pT, jet < 120 GeV/c in 0–10% and for 30 < pT, jet < 100 GeV/c in 10–30% collisions. Reconstructed jets were required to contain a leading charged particle with pT > 5 GeV/c to suppress jets constructed from the combinatorial background in Pb–Pb collisions. The leading charged particle requirement applied to jet spectra both in pp and Pb–Pb collisions had a negligible effect on the RAA. The nuclear modification factor RAA was found to be 0.28 ± 0.04 in 0–10% and 0.35 ± 0.04 in 10–30% collisions, independent of pT, jet within the uncertainties of the measurement. The observed suppression is in fair agreement with expectations from two model calculations with different approaches to jet quenching.
We have performed the first measurement of the coherent ψ(2S) photo production cross section in ultraperipheral Pb–Pb collisions at the LHC. This charmonium excited state is reconstructed via the ψ(2S) → l +l − and ψ(2S) → J/ψπ+π− decays, where the J/ψ decays into two leptons. The analysis is based on an event sample corresponding to an integrated luminosity of about 22 μb−1. The cross section for coherent ψ(2S) production in the rapidity interval −0.9 < y < 0.9 is dσcoh ψ(2S)/dy = 0.83±0.19 stat+syst mb. The ψ(2S) to J/ψ coherent cross section ratio is 0.34+0.08 −0.07(stat + syst). The obtained results are compared to predictions from theoretical models.
A measurement of dijet correlations in p–Pb collisions at √sNN = 5.02 TeV with the ALICE detector is presented. Jets are reconstructed from charged particles measured in the central tracking detectors and neutral energy deposited in the electromagnetic calorimeter. The transverse momentum of the full jet (clustered from charged and neutral constituents) and charged jet (clustered from charged particles only) is corrected event-by-event for the contribution of the underlying event, while corrections for underlying event fluctuations and finite detector resolution are applied on an inclusive basis. A projection of the dijet transverse momentum, kTy = pch+ne T,jet sin(ϕdijet) with ϕdijet the azimuthal angle between a full and charged jet and pch+ne T,jet the transverse momentum of the full jet, is used to study nuclear matter effects in p–Pb collisions. This observable is sensitive to the acoplanarity of dijet production and its potential modification in p–Pb collisions with respect to pp collisions. Measurements of the dijet kTy as a function of the transverse momentum of the full and recoil charged jet, and the event multiplicity are presented. No significant modification of kTy due to nuclear matter effects in p–Pb collisions with respect to the event multiplicity or a PYTHIA8 reference is observed.
The ALICE Collaboration at the LHC reports measurement of the inclusive production cross section of electrons from semi-leptonic decays of beauty hadrons with rapidity |y| < 0.8 and transverse momentum 1 < pT < 10 GeV/c, in pp collisions at √s = 2.76 TeV. Electrons not originating from semi-electronic decay of beauty hadrons are suppressed using the impact parameter of the corresponding tracks. The production cross section of beauty decay electrons is compared to the result obtained with an alternative method which uses the distribution of the azimuthal angle between heavy-flavour decay electrons and charged hadrons. Perturbative QCD predictions agree with the measured cross section within the experimental and theoretical uncertainties. The integrated visible cross section, σb→e = 3.47 ± 0.40(stat) +1.12 −1.33(sys) ± 0.07(norm) μb, was extrapolated to full phase space using Fixed Order plus Next-to-Leading Log (FONLL) calculations to obtain the total bb production ¯ cross section, σbb¯ = 130 ± 15.1(stat) +42.1 −49.8(sys) +3.4 −3.1(extr) ± 2.5(norm) ± 4.4(BR) μb.
Transverse momentum spectra of π±, K± and p(p¯) up to pT = 20 GeV/c at mid-rapidity in pp, peripheral (60–80%) and central (0–5%) Pb–Pb collisions at √sNN = 2.76 TeV have been measured using the ALICE detector at the Large Hadron Collider. The proton-to-pion and the kaon-to-pion ratios both show a distinct peak at pT ≈ 3 GeV/c in central Pb–Pb collisions. Below the peak, pT < 3 GeV/c, both ratios are in good agreement with hydrodynamical calculations, suggesting that the peak itself is dominantly the result of radial flow rather than anomalous hadronization processes. For pT > 10 GeV/c particle ratios in pp and Pb–Pb collisions are in agreement and the nuclear modification factors for π±, K± and p(p¯) indicate that, within the systematic and statistical uncertainties, the suppression is the same. This suggests that the chemical composition of leading particles from jets in the medium is similar to that of vacuum jets.